Araris生物技术公司与Chugai制药公司合作开发新的癌症治疗方法,可能价值780万加元。 Araris Biotech partners with Chugai Pharmaceutical to develop new cancer treatments, potentially worth $780M.

瑞士的一家公司Araris Biotech与Roche的日本子公司Chugai制药公司合作,开发新的抗体药物共产物(ADCs)。 Araris Biotech, a Swiss company, has partnered with Chugai Pharmaceutical, a Japanese subsidiary of Roche, to develop new antibody-drug conjugates (ADCs). Araris将利用其AraLinQTM平台创建这些ADCs,这可能导致癌症治疗的改善。 Araris will use its AraLinQ™ platform to create these ADCs, which could lead to improved cancer treatments. Chugai将支付预付费、基金研究以及处理未来的开发和销售,可能向阿拉里斯支付7.8亿美元的里程碑和特许权使用费。 Chugai will pay an upfront fee, fund research, and handle future development and sales, potentially paying Araris up to $780 million in milestones and royalties.